Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jul;67(1):3-5.
doi: 10.1165/rcmb.2022-0078ED.

Stem Cell-derived Nanovesicles for the Treatment of Pulmonary Hypertension: Are We There Yet?

Elena A Goncharova  1 , Laszlo Farkas  2
Affiliations
Editorial

Stem Cell-derived Nanovesicles for the Treatment of Pulmonary Hypertension: Are We There Yet?

Elena A Goncharova et al. Am J Respir Cell Mol Biol. 2022 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Antiproliferative and antiremodeling role of MSC-NVs in pulmonary hypertension as shown by the study of Hu and colleagues (6). Upper panel: Production of MSC-NVs from human umbilical cord mesenchymal stem cells. Left: Dysregulation of miR-125b-5p and miR-100-5p in lung tissue from patients with PAH and rats with monocrotaline-induced PH. Middle and right: Treatment with MSC-NVs carrying miR-125b-5p and miR-100-5p cargo decrease PDGF-induced proliferation and migration of PASMCs and reduce pulmonary vascular remodeling and PH in rats. MCT = monocrotaline; MSC-NVs = mesenchymal stem cells-derived nanovesicles; PAH = pulmonary arterial hypertension; PASMCs = pulmonary arterial smooth muscle cells; PDGF = platelet-derived growth factor; PH = pulmonary hypertension. Illustration created with BioRender.com.
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Pullamsetti SS, Savai R, Seeger W, Goncharova EA. Translational advances in the field of pulmonary hypertension. From cancer biology to new pulmonary arterial hypertension therapeutics. Targeting cell growth and proliferation signaling hubs. Am J Respir Crit Care Med . 2017;195:425–437. - PMC - PubMed
    1. Chun HJ, Bonnet S, Chan SY. Translational advances in the field of pulmonary hypertension. Translating microRNA biology in pulmonary hypertension. It will take more than “miR” words. Am J Respir Crit Care Med . 2017;195:167–178. - PMC - PubMed
    1. Fukumitsu M, Suzuki K. Mesenchymal stem/stromal cell therapy for pulmonary arterial hypertension: comprehensive review of preclinical studies. J Cardiol . 2019;74:304–312. - PubMed
    1. Klinger JR, Pereira M, Del Tatto M, Brodsky AS, Wu KQ, Dooner MS, et al. Mesenchymal stem cell extracellular vesicles reverse Sugen/hypoxia pulmonary hypertension in rats. Am J Respir Cell Mol Biol . 2020;62:577–587. - PMC - PubMed
    1. Willis GR, Kourembanas S, Mitsialis SA. Toward exosome-based therapeutics: isolation, heterogeneity, and fit-for-purpose potency. Front Cardiovasc Med . 2017;4:63. - PMC - PubMed